Submit your requirements and our technical
team will help.
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CS-1002 | CS-1002; SHR-8068 | Phase 3 Clinical | Cstone Pharmaceuticals | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Botensilimab | AGEN-1181 | Phase 3 Clinical | Agenus Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fibrolamellar hepatocellular carcinoma; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Liver Neoplasms; Melanoma; Microsatellite Instability; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Sturlimogene Erparepvec | RP-2 | Phase 3 Clinical | Replimune Group Inc | Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Precancerous Conditions; Stomach Neoplasms; Uveal melanoma | Details |
| Gotistobart | ONC-392; BNT316; BNT-316 | Phase 3 Clinical | Oncoimmune Inc | Anorectal disorders; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Melanoma; Metastatic breast cancer; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Erfonrilimab | KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms | Details |
| Volrustomig | MEDI5752; MEDI-5752 | Phase 3 Clinical | Medimmune Llc | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Mesothelioma; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Ipilimumab biosimilar (Henlius) | HLX13 | Phase 3 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Mesothelioma; Solid tumours | Details | |
| Nurulimab/Prolgolimab | BCD-217; BCD-145/BCD-100 | Phase 3 Clinical | BIOCAD JSC | Melanoma; Skin Melanoma | Details |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| Futermestotug | YH-001 | Phase 2 Clinical | Alopecia Areata; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma; Solid tumours | Details | |
| Danvilostomig | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| BMS-986288 | BMS-986288 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| Evalstotug | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | BeOne Medicines Ltd, Bioatla | Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms | Details |
| Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Ankang Biotechnology Co Ltd | Melanoma | Details | |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hormone-Resistant Prostate Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Clear Cell Carcinoma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Melanoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| Belatacept biosimilar (Alphamab) | KN-019 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Arthritis, Rheumatoid; Rejection of renal transplantation | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital of Navy Medical University | Pancreatic Neoplasms | Details | |
| Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
| Quavonlimab | AK-107; MK-1308 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details | |
| Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody AG, Ludwig Institute For Cancer Research | Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Hemangiosarcoma; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| KD-6001 | KD-6001 | Phase 2 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| Porustobart | HBM-4003; HCAb 4003-2 | Phase 2 Clinical | Harbour Biomed | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Neoplasms; Neuroendocrine Tumors; Solid tumours | Details |
| JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms | Details |
| Sovipostobart | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
| GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| Apalulizumab | Phase 2 Clinical | Shanghai Rui Jin Hospital | Pancreatic Neoplasms | Details | |
| Firastotug | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours | Details |
| LM-168 | LM-168 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours | Details |
| HX-044 | HX044; HX-044 | Phase 2 Clinical | Hanx Biopharmaceuticals Pty Ltd | Lymphoma; Solid tumours | Details |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Neoplasms; Solid tumours | Details |
| CS-2009 | CS-2009 | Phase 2 Clinical | Cstone Pharmaceuticals | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| COYA-302 | COYA 302; COYA-302; COYA302 | Phase 2 Clinical | Coya Therapeutics Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease | Details |
| HC-010(Shanghai Hongcheng) | HC-010; HC010 | Phase 2 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Efzilonkofusp alfa | GI-102 | Phase 2 Clinical | GI Innovation Inc | Astrocytoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Glioblastoma; Gliosarcoma; Liver Neoplasms; Melanoma; Ovarian Neoplasms; Skin Melanoma; Soft Tissue Neoplasms; Solid tumours | Details |
| SV-102 | SV-102; SV102; SYNC-T SV-102 | Phase 2 Clinical | Syncromune Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
| IMM-27M | IMM-27M; IMM27M; SYN27M; SYN-27M | Phase 2 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms; Pathologic Processes; Solid tumours | Details | |
| Vilastobart | XTX-101; XTX101 | Phase 2 Clinical | Xilio Development Inc | Colorectal Neoplasms | Details |
| RP-3 | RP-3 | Phase 2 Clinical | Replimune Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Muzastotug | ADG-126 | Phase 2 Clinical | Adagene Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liver Neoplasms; Solid tumours | Details |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| JS-007 | JS007; JS-007 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Carcinoma, Hepatocellular; Lung Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| KN-044 | KN-044 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| BMS-986218 (Bristol-Myers Squibb) | BMS-986218 | Phase 1 Clinical | Bristol-Myers Squibb Company | Adrenal Gland Neoplasms; Liver Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
| SAL-008 | SAL-008 | Phase 1 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Neoplasms | Details |
| GIGA-564 | GIGA-564 | Phase 1 Clinical | GigaGen Inc | Solid tumours | Details |
| CTLA-4 Mab (Beijng Immunoah Pharma Tech) | 5E3 (Beijng Immunoah Pharma Tech); CTLA-4 Mab (Beijng Immunoah Pharma Tech) | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
| GB-268 | GB268 | Phase 1 Clinical | Genor Biopharma Co Ltd | Neoplasms; Solid tumours | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
| GK-201 | GK201; GK-201 | Phase 1 Clinical | Suzhou Guokuang Pharmaceutical Tech Co Ltd | Solid tumours | Details |
| STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Anus Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| IMD-303 | IMD-303; IMD303 | Phase 1 Clinical | Shanghai Affinity Biopharmaceutical Co Ltd | Solid tumours | Details |
| Imiquimod/Zalifrelimab | UGN-302; UGN-201+UGN-301 | Phase 1 Clinical | Urogen Pharma | Urinary Bladder Neoplasms | Details |
| TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Melanoma; Solid tumours | Details |
| B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cadonilimab | AK-104; AK104 | Approved | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Lymphoma, T-Cell, Peripheral; Melanoma; Mesothelioma; Microsatellite Instability; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Diseases; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms; Vaginal Neoplasms; Vulvar Neoplasms | Details | |
| Ipilimumab | 10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; BMS-734016; Mab-10D14; MDX-101; MDX-010 | Approved | Bristol-Myers Squibb Company | Yervoy, 逸沃 | United States | Melanoma | Bristol-Myers Squibb Company | 2011-03-25 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adrenocortical Carcinoma; Angioimmunoblastic T-cell Lymphoma; Anus Neoplasms; Brain metastases; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Embryonal; Carcinoma, Endometrioid; Carcinoma, Giant Cell; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endodermal Sinus Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Gestational Trophoblastic Disease; Glioblastoma; Gliosarcoma; Hemangiosarcoma; HIV I | Details |
| IpilimumabN01 (Innovent Biologics) | IBI-310 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯欣 | Mainland China | Colonic Neoplasms | Innovent Biologics Inc | 2025-12-22 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Melanoma; Microsatellite Instability; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Solid tumours; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Tremelimumab | CP-675206; CP-675 | Approved | Pfizer Inc | IMJUDO | United States | Carcinoma, Hepatocellular | Astrazeneca Ab | 2022-10-21 | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Cystadenoma, Serous; Digestive System Diseases; Dysgerminoma; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatitis C, Chronic; HIV Infections; Hydronephrosis; Kidney Neoplasms; Klatskin Tumor; Laryngeal Diseases; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Cutaneous; Melanoma; Mesothelioma; Metastatic breast cancer; Microsatel | Details |
| Iparomlimab/Tuvonralimab | PBS-103/PBS-105; QL-1706; PSB-205 | Approved | Qilu Pharmaceutical Co Ltd | 齐倍安 | Mainland China | Uterine Cervical Neoplasms | Qilu Pharmaceutical Co Ltd | 2024-09-26 | Adenocarcinoma of Lung; Biliary Tract Neoplasms; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Diseases; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Intraepithelial Lesions of the Cervix; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |



